North Shore Private Hospital (Theranostics)

  • North Shore Radiology and Nuclear Medicine, North Shore Private Hospital, Westbourne Street, St Leonards NSW 2065

    Get directions

Theranostics

Located at the St. Leonards North Shore Hospital campus where GenesisCare are developing comprehensive, integrated cancer services. Currently, Theranostics treatments are provided at North Shore Radiology and Nuclear Medicine in North Shore Private Hospital but will soon be moving to a dedicated theranostics facility in the new North Shore Health Hub (Dexus) building on the North Shore hospital campus, due to open in mid-2021.

Our theranostics service is an evolving approach to cancer management, combining diagnostic imaging and radionuclide therapy. Most evidence to date is in metastatic castrate resistant prostate cancer and advanced neuroendocrine tumours (NETs).

Our team and expertise

Since 2016, GenesisCare has administered over 1000 treatment doses of 177Lutetium to more than 300 cancer patients in Australia. Patients have access to advanced theranostic treatment options using the latest technology, delivered by our highly experienced Nuclear Medicine team. Our clinical team are committed to the use of the latest technology and treatments.

What is involved?

Once a request for theranostics therapy is received, an initial consultation will be arranged for you to assess your suitability for treatment and to ensure that the therapy is provided appropriately and safely for each individual patient. The theranostics clinical research team will also assess whether you are eligible for any of the clinical trials that are currently taking place.

Treatments are performed as an outpatient and involve intravenous or oral hydration prior to, and following treatment administration, generally a period of approximately 4 hours at the facility will be required. Hospital admission is not required as the treatment is usually well tolerated.

Treatments are performed 6-8 weeks apart and 3-4 treatment cycles (up to 6) are required depending on treatment response and tolerability.

Types of theranostics treatments we offer

Theranostics can be used to treat cancers that have spread (metastasised), or where cancer is advanced and/or hasn’t responded to other treatments. While in the future theranostics may be used for different cancers, to date most experience and success has been in metastatic prostate cancer and neuroendocrine tumours.

  1. Treatment for advanced prostate cancer

    Lutetium-177 PSMA therapy (Lu-PSMA) is a new treatment for advanced prostate cancer. It delivers high doses of targeted radiation to the cancer sites. It’s used to specifically target the abnormal cells while limiting damage to surrounding healthy tissue.

    Learn more

  2. Treatment for advanced neuroendocrine tumours

    Lutetium-177 Octreotate therapy (Lu-Octreotate) is a treatment for advanced neuroendocrine tumours (NETs) or carcinoids.

    It delivers high doses of targeted radiation to the cancer sites. It’s used to specifically target the abnormal cells while limiting damage to surrounding healthy tissue. This therapy has been used for almost 20 years in this tumour type and is now approved for the treatment of progressive advanced neuroendocrine tumours in Europe and the USA.

    Learn more

Getting here